预约演示

更新于：2025-08-31

Hydrochlorothiazide

氢氯噻嗪

更新于：2025-08-31

概要

基本信息

简介氢氯噻嗪是一种小分子药物，作用于噻嗪类敏感氯化钠协同转运蛋白，是噻嗪类敏感氯化钠协同转运蛋白抑制剂。它的适应症包括尿崩症、水肿、高血压和肾结石等。氢氯噻嗪最初由诺华制药公司研发，并于1959年2月12日获得首次批准。该药物通过抑制NCC，减少肾脏中的钠重吸收，从而促进尿液排泄和水分排出，达到利尿的效果。此外，它还可以降低血压和防止肾结石形成。虽然氢氯噻嗪可以缓解症状，但也存在一些不良反应，如低钾血症、头晕、乏力等，需要在医生的指导下使用。总体而言，氢氯噻嗪是一种常用的利尿药和降压药，对多种疾病的治疗具有重要作用。

药物类型

小分子化药

别名

HCTZ、Hydrochlorothiazide (JP17/USP/INN)、氢氯噻嗪微片

+ [11]

靶点

NCC

作用方式

抑制剂

作用机制

NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

非在研适应症

原研机构

在研机构

+ [5]

非在研机构

Novartis AG

Novartis Pharmaceuticals Canada, Inc.

Novartis Pharmaceuticals Corp.

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1959-02-12),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C7H8ClN3O4S2

InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N

CAS号58-93-5

关联

254

项与氢氯噻嗪相关的临床试验

CTR20252112

/ RecruitingN/A

氢氯噻嗪微片在中国健康受试者中随机、开放、两制剂、单次给药、双周期、交叉的空腹及餐后状态下的生物等效性试验

主要目的：以LABORATOIRES JUVISE PHARMACEUTICALS的氢氯噻嗪片(商品名：ESIDREX®，规格：25 mg/片)为对照药，以北京科信必成医药科技发展有限公司委托河南力芯联创生物医药科技有限公司生产的氢氯噻嗪微片(规格：5 mg/片)为试验药，考察餐后和空腹条件下试验药与对照药在健康受试者中的药代动力学参数，评价两制剂的生物等效性。次要目的：评价中国健康受试者单次空腹及餐后口服试验药氢氯噻嗪微片和对照药氢氯噻嗪片后的安全性。

开始日期2025-06-20

申办/合作机构

北京科信必成医药科技发展有限公司

NCT07020104

/ RecruitingN/AIIT

The Role of Skin Sodium Accumulation in Chronic Kidney Disease

This project consists of four substudies: a cohort study (A) and a sodium intake intervention (B) and a sodium excretion intervention (C) and a water intervention study (D).
The main objective of the cohort study (A) is to investigate the prognostic implications of tissue sodium accumulation in CKD patients. The primary objective of the sodium intervention studies is to study the effect of high and low sodium intake (B) and increased renal sodium excretion (C) on tissue sodium content. The main objective of the water intervention study (D) is to investigate the effect of increased and habitual water intake on tissue sodium content and transepidermal water loss.

开始日期2025-01-07

申办/合作机构

Nierstichting Nederland

CTR20243533

/ CompletedN/A

氢氯噻嗪片（25mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

主要研究目的：按有关生物等效性试验的规定，选择Laboratoires Juvise Pharmaceuticals为持证商的氢氯噻嗪片（商品名：ESIDREX，规格：25mg）为参比制剂，对辰欣药业股份有限公司生产并提供的受试制剂氢氯噻嗪片（规格：25mg）进行空腹和餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹和餐后给药条件下的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂氢氯噻嗪片（规格：25mg）和参比制剂氢氯噻嗪片（商品名：ESIDREX，规格：25mg）的安全性。

开始日期2024-10-24

申办/合作机构

辰欣药业股份有限公司

100 项与氢氯噻嗪相关的临床结果

登录后查看更多信息

100 项与氢氯噻嗪相关的转化医学

登录后查看更多信息

100 项与氢氯噻嗪相关的专利（医药）

登录后查看更多信息

12,278

项与氢氯噻嗪相关的文献（医药）

2025-12-01·Water Research X

Micropollutants removal, residual risk, and costs for quaternary treatments in the framework of the Urban Wastewater Treatment Directive

作者: Antonelli, Manuela ; Piraldi, Sara ; Ianes, Jessica ; Cantoni, Beatrice

The revised Urban Wastewater Treatment Directive (UWWTD) imposes stringent regulations for the removal of micropollutants from urban wastewater treatment plants.The analyses conducted in this study are based on current knowledge extrapolated from literature WWTPs, to investigate the occurrence, removal and environmental risk related to the 12 target micropollutants: Amisulpride, Benzotriazole, 4,5-Methylbenzotriazole, Carbamazepine, Clarithromycin, Citalopram, Candesartan, Diclofenac, Hydrochlorothiazide, Irbesartan, Metoprolol, and Venlafaxine.The goal is to provide valuable insights into the challenges and opportunities associated with implementing quaternary treatment processes to comply with the UWWTD.It indicate that the conventional biol. treatment is insufficient, with median removal rates below 50% for most target micropollutants (except for Benzotriazole and Irbesartan).The implementation of quaternary treatment processes, namely ozonation and activated carbon adsorption, significantly enhances WWTP micropollutants removal, with median removal efficiencies exceeding 80% for all the target micropollutants, with Candesartan being the most recalcitrant.Environmental risk assessment reveals that some micropollutants pose a significant threat to aquatic ecosystems even with 80% removal efficiency (Irbesartan, Candesartan, Diclofenac, and Venlafaxine), while others do not pose a risk even at WWTP influent concentrations (4,5-Methylbenzotriazole, Hydrochlorothiazide, Amisulpride, Citalopram, and Metoprolol).Economic anal. shows that the selection of specific operating parameter values significantly impacts the cost of each treatment process, changing the economic feasibility ranking of the different treatment options.

2025-11-01·Current Drug Safety

Diuretics-Induced Acute Pancreatitis: Case Series with a Review of the Literature

Review

作者: Patel, Dhruvkumar M. ; Patel, Lalitkumar B. ; Patel, Vahin B ; Patel, Mukundkumar V. ; Patel, Dhara K. ; Patel, Maitri M.

Background::

Although diuretic-induced Acute Pancreatitis (AP) cases are typically mild to moderate, severe and potentially fatal occurrences can arise.

Case Series and Literature Review::

We have, herein, presented a series of diuretic-induced AP cases from March 2018 to February 2024 of a 54-year-old woman treated with chlorthalidone, a 45-year-old male treated with hydrochlorothiazide, and a 48-year-old male treated with frusemide. The literature search has identified 26 cases published to date, 10 from frusemide and 16 from thiazide diuretics. The Naranjo adverse reaction probability scale has categorized all three drugs as “probable”. All cases have responded to conservative treatment and cessation of the offending drug. Various mechanisms, such as hypersensitization, ischemia, direct cytotoxic effects, hypercalcemia, and dose-dependent idiosyncrasy, have been found to lead to intrapancreatic activation of pancreatic enzymes, resulting in drug-induced AP.

Conclusion::

Further research into the mechanisms and genetic factors contributing to diureticinduced AP is essential for enabling early diagnosis and management of diuretic-induced AP.

2025-11-01·AMERICAN HEART JOURNAL

Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction

Article

作者: Thorvaldsen, Tonje ; Savarese, Gianluigi ; Guidetti, Federica ; Hage, Camilla ; Szabó-Söderberg, Barna ; Pitt, Bertram ; Lund, Lars H ; Benson, Lina

BACKGROUND:

Trials in heart failure with preserved ejection fraction (HFpEF) frequently apply baseline diuretic use as enrichment criterion. However, the role of thiazides and loop diuretic dose for enrichment is unclear. We aimed to assess baseline loop and thiazide diuretic use, loop diuretic dose, and associations with cardiovascular (CV) outcomes in HFpEF.

METHODS:

We performed a post-hoc analysis of TOPCAT-Americas. The primary outcome was CV death and total hospitalizations for heart failure (HHF).

RESULTS:

1765 patients were followed for a median of 2.9 years. At baseline, loop diuretic monotherapy was used in 67%, thiazide monotherapy in 10% and the combination in 12%. Loop diuretic monotherapy and combined loop+thiazide diuretic treatment were associated with higher risk of the primary outcome (HR 1.59, 95% CI 1.23-2.07, P < .001; and HR 2.07, 95% CI 1.55-2.76, P < .001 respectively), as well as first HHF, total HHFs and the composite of first HHF or CV death. Only combined loop+thiazide diuretic therapy was associated with CV death alone (HR 1.85, 95% CI 1.13-3.04, P = .015). For all above endpoints, the combined diuretic therapy was associated with greater risk than loop diuretics alone. Thiazide monotherapy was not associated with any endpoints. Higher baseline loop diuretic doses were associated with higher risk of all outcomes.

CONCLUSION:

In HFpEF, baseline use and higher doses of loop diuretics were associated with higher risk of CV death and total HHFs. Thiazide alone was not associated with any endpoints, but when added to loop diuretics it was associated with additional risk for all outcomes.

项与氢氯噻嗪相关的新闻（医药）

2025-08-29

·EINPresswire

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

2025-08-29

·EINPresswire

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

2025-08-24

·信狐药迅

四十个1类创新药获批临床、一个进口品种收到通知件| 新获批(8.18-8.24）

每周药品注册获批数据，分门别类呈现，一目了然。(8.18-8.24）新药上市申请无新药临床申请药品名称企业注册分类受理号 IBI3032 信达生物科技有限公司 1 CXHL2500702 IBI3032 信达生物科技有限公司 1 CXHL2500701 IBI3032 信达生物科技有限公司 1 CXHL2500700 IBI3032 信达生物科技有限公司 1 CXHL2500699 ICP-248片北京诺诚健华医药科技有限公司 1 CXHL2500610 ICP-248片北京诺诚健华医药科技有限公司 1 CXHL2500609 丁二酸复瑞替尼胶囊复星万邦(江苏)医药集团有限公司 1 CXHL2500591 F-02-2-Na片广东横琴新创益生物医药有限公司 1 CXHL2500589 F-02-2-Na片广东横琴新创益生物医药有限公司 1 CXHL2500588 F-02-2-Na片湘北威尔曼制药股份有限公司 1 CXHL2500587 SIM0508片上海先祥医药科技有限公司 1 CXHL2500584 SIM0508片上海先祥医药科技有限公司 1 CXHL2500583 ABSK043片上海和誉生物医药科技有限公司 1 CXHL2500582 ABSK043片上海和誉生物医药科技有限公司 1 CXHL2500581 HP-001胶囊上海超阳药业有限公司 1 CXHL2500580 HP-001胶囊上海超阳药业有限公司 1 CXHL2500579 HP-001胶囊上海超阳药业有限公司 1 CXHL2500578 注射用FZ-P001钠上海复旦张江生物医药股份有限公司 1 CXHL2500576 LY104注射液青岛海洋生物医药研究院 1 CXHL2500557 LY104注射液青岛海洋生物医药研究院 1 CXHL2500556 HRS-7172片江苏恒瑞医药股份有限公司 1 CXHL2500568 HRS-7172片江苏恒瑞医药股份有限公司 1 CXHL2500567 HRS-7172片江苏恒瑞医药股份有限公司 1 CXHL2500566 RSS0393软膏瑞石生物医药有限公司 1 CXHL2500564 RSS0393软膏瑞石生物医药有限公司 1 CXHL2500563 RSS0393软膏瑞石生物医药有限公司 1 CXHL2500562 D-2570片益方生物科技(上海)股份有限公司 1 CXHL2500560 HRS-4729注射液福建盛迪医药有限公司 1 CXHL2500559 HRS-4729注射液福建盛迪医药有限公司 1 CXHL2500558 INT-210胶囊宜坤行健生物医药(上海)有限公司 1 CXHL2500554 INT-210胶囊宜坤行健生物医药(上海)有限公司 1 CXHL2500553 注射用HTMC0769 上海壹典医药科技开发有限公司 1 CXHL2500546 WJ22096片南京境奥生物医药科技有限公司 1 CXHL2500543 WJ22096片南京境奥生物医药科技有限公司 1 CXHL2500542 MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司 1 CXHL2500531 MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司 1 CXHL2500530 HB5凝胶北京中科先行医疗科技有限公司 1 CXHL2500536 HB5凝胶北京中科先行医疗科技有限公司 1 CXHL2500535 HB5凝胶北京中科先行医疗科技有限公司 1 CXHL2500534 XC2309注射液浙江医药股份有限公司新昌制药厂 1 CXHL2500533 司美格鲁肽注射液福建基诺厚普生物科技有限公司 2.2 CXHL2500574 司美格鲁肽注射液福建基诺厚普生物科技有限公司 2.2 CXHL2500573 司美格鲁肽注射液福建基诺厚普生物科技有限公司 2.2 CXHL2500572 司美格鲁肽注射液福建基诺厚普生物科技有限公司 2.2 CXHL2500571 司美格鲁肽注射液福建基诺厚普生物科技有限公司 2.2 CXHL2500570 JSS-222 江西施美药业股份有限公司 2.2 CXHL2500575 SPIEC肠溶微片吉林天衡药业有限公司 2.2 CXHL2500551 CZ006注射液浙江萃泽医药科技有限公司 2.2 CXHL2500520 硫酸阿托品滴眼液湖南迈欧医疗科技有限公司 2.2 CXHL2500516 硫酸阿托品滴眼液湖南迈欧医疗科技有限公司 2.2 CXHL2500517 奥曲肽长效注射液石药集团中奇制药技术(石家庄)有限公司 2.2;2.4 CXHL2500585 盐酸吉卡昔替尼片苏州泽璟生物制药股份有限公司 2.4 CXHL2500577 盐酸吉卡昔替尼片苏州泽璟生物制药股份有限公司 2.4 CXHL2500552 JLM019注射液杰库(上海)生物医药研究有限公司 1 CXSL2500496 注射用HS-20093 上海翰森生物医药科技有限公司 1 CXSL2500490 IBI343 信达生物制药(苏州)有限公司 1 CXSL2500487 注射用ZG005 苏州泽璟生物制药股份有限公司 1 CXSL2500486 洛奈利单抗注射液山东新时代药业有限公司 1 CXSL2500485 CVL006 注射液甫康(上海)健康科技有限责任公司 1 CXSL2500477 注射用SHR-A2009 苏州盛迪亚生物医药有限公司 1 CXSL2500476 注射用ZG005 苏州泽璟生物制药股份有限公司 1 CXSL2500473 注射用SLN12140 领诺(上海)医药科技有限公司 1 CXSL2500472 注射用ZGGS18 苏州泽璟生物制药股份有限公司 1 CXSL2500471 AK131注射液中山康方生物医药有限公司 1 CXSL2500484 AK109注射液康融东方(广东)医药有限公司 1 CXSL2500482 AK117注射液中山康方生物医药有限公司 1 CXSL2500481 AK117注射液中山康方生物医药有限公司 1 CXSL2500480 CM536注射液康诺亚生物医药科技(成都)有限公司 1 CXSL2500474 GR1802注射液重庆智翔金泰生物制药股份有限公司 1 CXSL2500470 GR1802注射液重庆智翔金泰生物制药股份有限公司 1 CXSL2500469 注射用QLS31905 齐鲁制药有限公司 1 CXSL2500466 注射用SSS50 沈阳三生制药有限责任公司 1 CXSL2500458 HJY-ATRQβ-001注射液武汉华纪元生物技术开发有限公司 1 CXSL2500463 UC101 CAR-T细胞注射液成都优赛诺生物科技有限公司 1 CXSL2500451 TI-0093注射液圆因(北京)生物科技有限公司 1 CXSL2500461 KM1溶瘤痘苗病毒注射液深圳市华药康明生物药业有限责任公司 1 CXSL2500446 怡培生长激素注射液厦门特宝生物工程股份有限公司 2.2 CXSL2500493 SHR-8068注射液苏州盛迪亚生物医药有限公司 2.2 CXSL2500495 阿得贝利单抗注射液上海盛迪医药有限公司 2.2 CXSL2500491 QL2107注射液齐鲁制药有限公司 2.2 CXSL2500467 司普奇拜单抗注射液成都康诺行生物医药科技有限公司 2.2 CXSL2500454 仿制药申请药品名称企业注册分类受理号氢氯噻嗪珠海润都制药股份有限公司 CYHS2460314 贝美前列素涂剂浙江孚诺医药股份有限公司 3 CYHL2500113 雷美替胺片朗天药业(湖北)有限公司 3 CYHL2500112 甲苯磺酸卢美哌隆胶囊荣昌制药(淄博)有限公司 3 CYHL2500111 洛索洛芬钠凝胶贵州联盛药业有限公司 3 CYHL2500110 洛索洛芬钠凝胶贵州联盛药业有限公司 3 CYHL2500109 利多卡因丙胺卡因牙周凝胶深圳珐玛易药品科技有限公司 3 CYHL2500103 硫酸特布他林注射液广东万泰科创药业有限公司 3 CYHL2500102 黄体酮阴道缓释凝胶河北新张药股份有限公司 4 CYHL2500115 多种油脂肪乳注射液(C6-24) 成都国为生物医药有限公司 4 CYHL2500104 冻干b型流感嗜血杆菌结合疫苗艾美坚持生物制药有限公司 3.3 CXSL2500442 SYS6036注射液石药集团巨石生物制药有限公司 3.3 CXSL2500500 度普利尤单抗注射液石药集团巨石生物制药有限公司 3.3 CXSL2500453 度普利尤单抗注射液石药集团巨石生物制药有限公司 3.3 CXSL2500452 进口申请药品名称企业注册分类受理号注射用A型肉毒毒素 Daewoong Pharmaceutical Co., Ltd. 3.4 JXSS2200009国;JXSS2200009 BMS-986504片 Bristol-Myers Squibb Company 1 JXHL2500187 PF-07248144片 Pfizer Inc. 1 JXHL2500149 PF-07248144片 Pfizer Inc. 1 JXHL2500148 AZD6793 AstraZeneca AB 1 JXHL2500142 AZD6793 AstraZeneca AB 1 JXHL2500141 AZD6793 AstraZeneca AB 1 JXHL2500140 BMS-986504片 Bristol-Myers Squibb Company 1 JXHL2500139 Baxdrostat片 AstraZeneca AB 1 JXHL2500138 Baxdrostat片 AstraZeneca AB 1 JXHL2500137 ARV-471(PF-07850327)片 Pfizer Inc. 1 JXHL2500136 PF-07248144片 Pfizer Inc. 1 JXHL2500135 PF-07248144片 Pfizer Inc. 1 JXHL2500134 PF-07248144片 Pfizer Inc. 1 JXHL2500133 BI 690517片 Boehringer Ingelheim International GmbH 1 JXHL2500132 Muvalaplin片 Eli Lilly and Company 1 JXHL2500131 甲苯磺酸利特昔替尼胶囊 Pfizer Inc. 2.4 JXHL2500144 甲苯磺酸利特昔替尼胶囊 Pfizer Inc. 2.4 JXHL2500143 BMS-986165片 Bristol-Myers Squibb Company 2.4 JXHL2500124 BMS-986165片 Bristol-Myers Squibb Company 2.4 JXHL2500123 AMG 133 Amgen Inc. 1 JXSL2500096 AMG 133 Amgen Inc. 1 JXSL2500095 AMG 133 Amgen Inc. 1 JXSL2500094 AMG 133 Amgen Inc. 1 JXSL2500093 AMG 133 Amgen Inc. 1 JXSL2500092 AMG 133 Amgen Inc. 1 JXSL2500091 注射用MK-2400 Merck Sharp & Dohme LLC 1 JXSL2500089 注射用MK-5909 Merck Sharp & Dohme LLC 1 JXSL2500088 注射用MK-1022 Merck Sharp & Dohme LLC 1 JXSL2500086 注射用贝林妥欧单抗(皮下注射) Amgen Inc. 2.1 JXSL2500098 注射用贝林妥欧单抗(皮下注射) Amgen Inc. 2.1 JXSL2500097 注射用德曲妥珠单抗 Daiichi Sankyo, Inc. 2.2 JXSL2500101 比奇珠单抗注射液 UCB Pharma S.A. 2.2 JXSL2500100 比奇珠单抗注射液 UCB Pharma S.A. 2.2 JXSL2500099 Dostarlimab注射液 GlaxoSmithKline (Ireland) Limited 3.1 JXSL2500087 中药相关申请药品名称企业注册分类受理号复方黄杞颗粒浙江九如医药科技有限公司 1.1 CXZL2500036 JMZ-2102胶囊江西济民可信药业有限公司 1.2 CXZL2500034 JMZ-2102 江西济民可信药业有限公司 1.2 CXZL2500033 金振口服液江苏康缘药业股份有限公司 2.3 CXZL2500038 黄厚止泻滴丸安徽雷允上药业有限公司 2.3 CXZL2500035 注：橙色字体部分结论为不批准或收到通知件；

申请上市临床申请临床1期

100 项与氢氯噻嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00340	氢氯噻嗪	C03AA03	DB00999

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾病综合征	美国	Novitium Pharma LLC	2025-01-28
尿崩症	中国	远大医药集团	1981-01-01
水肿	中国	宜昌人福药业有限责任公司	1981-01-01
肾石病	中国	天津力生制药股份有限公司	1981-01-01
高血压	美国	Novartis Pharmaceuticals Corp.	1959-02-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	-	Boehringer Ingelheim GmbH	1998-06-01
2型糖尿病	临床2期	加拿大	Novartis Pharmaceuticals Canada, Inc.	2012-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02373163 (INTERVENCION Trial \| INTERVENCION, CTgov)	临床4期	高血压	166	Hydrochlorothiazide (Diuretic)	積製鏇網憲淵糧築齋膚(構鏇鹽簾鏇顧糧鹹夢鑰) = 鏇憲齋蓋鹹繭製構窪願鹹範醖範齋蓋鬱醖鹽壓 (繭顧製蓋製鏇繭膚鬱願, 8.4) 更多	-	2025-07-29
				Amlodipine (Calcium-channel Blocker)	積製鏇網憲淵糧築齋膚(構鏇鹽簾鏇顧糧鹹夢鑰) = 淵襯廠蓋夢齋繭膚積製鹹範醖範齋蓋鬱醖鹽壓 (繭顧製蓋製鏇繭膚鬱願, 9.2) 更多
NCT03295734 (ACES, CTgov)	临床2期	高血压	223	Aerobic exercise+Perindopril (Perindopril)	鏇積壓遞鑰積壓憲齋憲(餘構蓋簾積鹽積糧膚繭) = 膚築遞製襯築窪蓋蓋觸鹽襯製餘鹽範糧範鏇膚 (鏇憲艱窪範糧鏇鬱淵襯, 觸積築夢襯夢襯廠醖構 ~ 淵夢憲糧糧鏇觸窪窪鹽) 更多	-	2025-07-22
				Aerobic exercise+Losartan (Losartan)	鏇積壓遞鑰積壓憲齋憲(餘構蓋簾積鹽積糧膚繭) = 窪壓遞繭夢製積製窪糧鹽襯製餘鹽範糧範鏇膚 (鏇憲艱窪範糧鏇鬱淵襯, 蓋襯製襯齋選衊選觸壓 ~ 夢夢網願艱觸簾繭膚鏇) 更多
NCT00690521 (CTgov)	N/A	心脏衰竭 \| 慢性充血性心力衰竭	8	Arm1+Hydrochlorothiazide+Metolazone+Furosemide (Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone)	艱夢構襯選積夢襯鹹製 = 網廠廠鏇窪構鹹艱繭觸願鹹齋膚築餘製願繭衊 (選餘餘蓋糧襯艱壓簾選, 觸顧齋顧膚遞構獵鑰獵 ~ 蓋餘襯壓鹹廠醖鬱淵膚) 更多	-	2024-10-10
				Arm2+Hydrochlorothiazide+Metolazone+Furosemide (Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide)	艱夢構襯選積夢襯鹹製 = 衊積壓網壓願獵艱積鏇願鹹齋膚築餘製願繭衊 (選餘餘蓋糧襯艱壓簾選, 獵糧製觸衊顧襯餘願壓 ~ 艱構獵願廠積齋鬱遞齋) 更多
NCT02185417 (Diuretic Comparison Project (DCP), Pubmed \| JAMA Netw Open) 人工标引	临床3期	高血压	13,523	Chlorthalidone (with prior MI or stroke at baseline)	積遞鬱醖網齋鹹鏇襯顧(窪廠鬱製鹽繭糧繭艱齋) = 積鹹餘觸繭簾鏇壓齋鹹觸夢簾顧積觸範積範築 (遞網淵糧簾製壓獵夢膚 ) 更多	积极	2024-05-01
				Hydrochlorothiazide (with prior MI or stroke at baseline)	積遞鬱醖網齋鹹鏇襯顧(窪廠鬱製鹽繭糧繭艱齋) = 鏇遞憲觸糧憲遞鹹構製觸夢簾顧積觸範積範築 (遞網淵糧簾製壓獵夢膚 ) 更多
NCT03057431 (NOSTONE, CTgov)	临床3期	肾结石	416	Placebo oral capsule (Placebo)	廠簾齋積衊遞鬱願簾膚 = 窪願網選餘網齋艱鹹鏇憲鏇齋窪艱艱夢淵醖夢 (選壓膚鬱壓衊鑰餘選鏇, 艱鹹餘製繭構簾鬱憲憲 ~ 淵醖鹹憲網遞襯鏇願夢) 更多	-	2024-02-01
				12.5 mg hydrochlorothiazide (12.5 mg Hydrochlorothiazide)	廠簾齋積衊遞鬱願簾膚 = 鬱廠繭糧襯鏇製積醖構憲鏇齋窪艱艱夢淵醖夢 (選壓膚鬱壓衊鑰餘選鏇, 獵網鏇範鏇範窪艱襯觸 ~ 餘積鬱醖繭鑰積餘鹹積) 更多
NCT01647932 (CLOROTIC, Pubmed) 人工标引	临床3期	急性失代偿性心力衰竭	230	Placebo	蓋網醖簾齋構遞鹹簾淵(夢醖夢構夢顧獵鑰鑰廠) = The addition of HCTZ to furosemide was associated to a greatest weight loss at 72/96 h, better metrics of diuretic response and higher 24-h diuresis compared to placebo without significant differences according to sex 築壓獵鏇夢憲製襯鹹鹽 (襯範觸繭範鹹簾鹽蓋製 ) 更多	积极	2024-01-11
				furosemide+hydrochlorothiazide
NCT04334824 (Pubmed)	N/A	黑色素瘤 \| 恶性上皮肿瘤	2,953,748	Hydrochlorothiazide	餘窪壓構積築獵簾遞鹽(網網齋壓齋顧範糧繭獵): HR = 1.12 (95% CI, 1.03 ~ 1.21), P-Value = ≥10 years	不佳	2023-04-25
				Angiotensin-converting enzyme inhibitors (ACEIs)
NCT03461003 (NICHE, CTgov)	临床4期	高血压	49	NICHE method+Lisinopril+Hydrochlorothiazide+Amlodipine+Losartan (NICHE Method)	餘範衊鹽鹽願醖積艱襯(廠鬱鹹繭襯蓋淵顧齋窪) = 窪願範糧糧積廠糧顧鹽選衊壓繭構鹽夢願願餘 (壓築簾遞製鬱遞顧獵窪, 9.301) 更多	-	2022-09-09
				Usual care (Usual Care)	餘範衊鹽鹽願醖積艱襯(廠鬱鹹繭襯蓋淵顧齋窪) = 製齋憲鏇膚製遞壓衊積選衊壓繭構鹽夢願願餘 (壓築簾遞製鬱遞顧獵窪, 9.586) 更多
NCT00667719 (CTgov)	临床3期	原发性高血压	564	Hydrochlorothiazide+Aliskiren+Amlodipine	鏇願簾觸遞獵壓醖衊築(襯壓鹹蓋淵築範艱廠構) = 壓蓋衊糧淵蓋製憲遞鑰網鏇選淵醖範製衊選簾 (餘製製淵衊鑰憲廠蓋衊, 7.74) 更多	-	2021-06-07
NCT02699125 (guanhctz, CTgov)	临床4期	阻塞性睡眠呼吸暂停综合征 \| 高血压	41	Placebo (Placebo)	夢願範淵蓋壓願遞簾蓋(鹽窪築夢廠鏇網淵廠網) = 製廠願遞淵蓋艱鑰齋願鏇繭簾鹹簾顧艱繭鬱糧 (憲餘壓憲齋鏇餘繭淵網, 4.2) 更多	-	2020-12-04
				Guanfacine (Guanfacine)	夢願範淵蓋壓願遞簾蓋(鹽窪築夢廠鏇網淵廠網) = 獵鹽艱簾齋廠餘夢壓膚鏇繭簾鹹簾顧艱繭鬱糧 (憲餘壓憲齋鏇餘繭淵網, 2.9) 更多